-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
-
Summary
-
CRISPR Therapeutics AG quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2016 to 2023.
- CRISPR Therapeutics AG Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2024 was $306M, a 5561% increase year-over-year.
- CRISPR Therapeutics AG annual Net Cash Provided by (Used in) Financing Activities for 2023 was $62.7M, a 62.4% increase from 2022.
- CRISPR Therapeutics AG annual Net Cash Provided by (Used in) Financing Activities for 2022 was $38.6M, a 84.6% decline from 2021.
- CRISPR Therapeutics AG annual Net Cash Provided by (Used in) Financing Activities for 2021 was $251M, a 75.3% decline from 2020.
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)